Literature DB >> 25342094

Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor.

Michael T Reinartz1, Solveig Kälble, Timo Littmann, Takeaki Ozawa, Stefan Dove, Volkhard Kaever, Irving W Wainer, Roland Seifert.   

Abstract

Functional selectivity is well established as an underlying concept of ligand-specific signaling via G protein-coupled receptors (GPCRs). Functionally, selective drugs could show greater therapeutic efficacy and fewer adverse effects. Dual coupling of the β2-adrenoceptor (β2AR) triggers a signal transduction via Gsα and Giα proteins. Here, we examined 12 fenoterol stereoisomers in six molecular and cellular assays. Using β2AR-Gsα and β2AR-Giα fusion proteins, (R,S')- and (S,S')-isomers of 4'-methoxy-1-naphthyl-fenoterol were identified as biased ligands with preference for Gs. G protein-independent signaling via β-arrestin-2 was disfavored by these ligands. Isolated human neutrophils constituted an ex vivo model of β2AR signaling and demonstrated functional selectivity through the dissociation of cAMP accumulation and the inhibition of formyl peptide-stimulated production of reactive oxygen species. Ligand bias was calculated using an operational model of agonism and revealed that the fenoterol scaffold constitutes a promising lead structure for the development of Gs-biased β2AR agonists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25342094     DOI: 10.1007/s00210-014-1054-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  49 in total

Review 1.  Effect of beta-agonists on inflammatory cells.

Authors:  P J Barnes
Journal:  J Allergy Clin Immunol       Date:  1999-08       Impact factor: 10.793

Review 2.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 3.  The superoxide-forming NADPH oxidase of phagocytes. An enzyme system regulated by multiple mechanisms.

Authors:  R Seifert; G Schultz
Journal:  Rev Physiol Biochem Pharmacol       Date:  1991       Impact factor: 5.545

4.  Beta-arrestins specifically constrain beta2-adrenergic receptor signaling and function in airway smooth muscle.

Authors:  Deepak A Deshpande; Barbara S Theriot; Raymond B Penn; Julia K L Walker
Journal:  FASEB J       Date:  2008-03-12       Impact factor: 5.191

5.  Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy.

Authors:  Emma T van der Westhuizen; Billy Breton; Arthur Christopoulos; Michel Bouvier
Journal:  Mol Pharmacol       Date:  2013-12-23       Impact factor: 4.436

6.  Identification of novel functionally selective κ-opioid receptor scaffolds.

Authors:  Kate L White; Alex P Scopton; Marie-Laure Rives; Ruslan V Bikbulatov; Prabhakar R Polepally; Peter J Brown; Terrance Kenakin; Jonathan A Javitch; Jordan K Zjawiony; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

Review 7.  Novel GPCR paradigms at the μ-opioid receptor.

Authors:  G L Thompson; E Kelly; A Christopoulos; M Canals
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

8.  Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.

Authors:  Anthony Yiu-Ho Woo; Tian-Bing Wang; Xiaokun Zeng; Weizhong Zhu; Darrell R Abernethy; Irving W Wainer; Rui-Ping Xiao
Journal:  Mol Pharmacol       Date:  2008-10-07       Impact factor: 4.436

Review 9.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

10.  Dissociations in the effects of β2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity.

Authors:  Irena Brunskole Hummel; Michael T Reinartz; Solveig Kälble; Heike Burhenne; Frank Schwede; Armin Buschauer; Roland Seifert
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more
  10 in total

1.  Interaction of fenoterol stereoisomers with β2-adrenoceptor-G sα fusion proteins: antagonist and agonist competition binding.

Authors:  Michael T Reinartz; Solveig Kälble; Irving W Wainer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-31       Impact factor: 3.000

2.  Naunyn-Schmiedeberg's Archives of Pharmacology under new editorship: change and continuity.

Authors:  Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-24       Impact factor: 3.000

3.  Lack of Gαi2 leads to dilative cardiomyopathy and increased mortality in β1-adrenoceptor overexpressing mice.

Authors:  Kirsten Keller; Martina Maass; Sara Dizayee; Veronika Leiss; Suvi Annala; Jessica Köth; Wiebke K Seemann; Jochen Müller-Ehmsen; Klaus Mohr; Bernd Nürnberg; Stefan Engelhardt; Stefan Herzig; Lutz Birnbaumer; Jan Matthes
Journal:  Cardiovasc Res       Date:  2015-10-13       Impact factor: 10.787

4.  GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts.

Authors:  Michel Bernier; Jonathan Catazaro; Nagendra S Singh; Artur Wnorowski; Anna Boguszewska-Czubara; Krzysztof Jozwiak; Robert Powers; Irving W Wainer
Journal:  Int J Cancer       Date:  2017-08-07       Impact factor: 7.396

5.  Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands.

Authors:  Timo Littmann; Martin Göttle; Michael T Reinartz; Solveig Kälble; Irving W Wainer; Takeaki Ozawa; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2015-08-25       Impact factor: 4.030

6.  GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014.

Authors:  Alexander Heifetz; Gebhard F X Schertler; Roland Seifert; Christopher G Tate; Patrick M Sexton; Vsevolod V Gurevich; Daniel Fourmy; Vadim Cherezov; Fiona H Marshall; R Ian Storer; Isabel Moraes; Irina G Tikhonova; Christofer S Tautermann; Peter Hunt; Tom Ceska; Simon Hodgson; Mike J Bodkin; Shweta Singh; Richard J Law; Philip C Biggin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-03-14       Impact factor: 3.000

Review 7.  Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology.

Authors:  Zuzana Bologna; Jian-Peng Teoh; Ahmed S Bayoumi; Yaoliang Tang; Il-Man Kim
Journal:  Biomol Ther (Seoul)       Date:  2017-01-01       Impact factor: 4.634

8.  Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased β2 adrenergic agonist.

Authors:  Artur Wnorowski; Danuta Dudzik; Michel Bernier; Jakub Wójcik; Guido Keijzers; Alberto Diaz-Ruiz; Karolina Mazur; Yongqing Zhang; Haiyong Han; Morten Scheibye-Knudsen; Krzysztof Jozwiak; Coral Barbas; Irving W Wainer
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

Review 9.  Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.

Authors:  Kelly A Berg; William P Clarke
Journal:  Int J Neuropsychopharmacol       Date:  2018-10-01       Impact factor: 5.176

Review 10.  β adrenergic receptor modulated signaling in glioma models: promoting β adrenergic receptor-β arrestin scaffold-mediated activation of extracellular-regulated kinase 1/2 may prove to be a panacea in the treatment of intracranial and spinal malignancy and extra-neuraxial carcinoma.

Authors:  George Zaki Ghali; Michael George Zaki Ghali
Journal:  Mol Biol Rep       Date:  2020-04-18       Impact factor: 2.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.